Teladoc posts FY 2025 net loss of USD 200.3 million, down 80%

Reuters

02/26

Teladoc posts FY 2025 net loss of USD 200.3 million, down 80%

Teladoc Health reported Q4 2025 revenue of USD 642.3 million (flat), with net loss of USD 25.1 million and adjusted EBITDA of USD 83.8 million (+12%). For FY 2025, revenue was USD 2.53 billion (-2%), net loss was USD 200.3 million, adjusted EBITDA was USD 281.1 million (-10%), operating cash flow was USD 294.4 million (flat) and free cash flow was USD 166.9 million (-2%); the company ended 2025 with USD 781.1 million in cash and cash equivalents. In Q4, Integrated Care revenue was USD 409.1 million (+5%) while BetterHelp revenue was USD 233.2 million (-7%); Integrated Care adjusted EBITDA was USD 65.3 million (+23%) and BetterHelp adjusted EBITDA was USD 18.5 million (-15%). Teladoc Health said it strengthened its product portfolio and advanced innovation across Integrated Care and BetterHelp, while maintaining a focus on disciplined execution and leveraging technology to meet evolving client and member needs. For FY 2026, Teladoc Health guided for revenue of USD 2.47 billion to USD 2.587 billion and adjusted EBITDA of USD 266 million to USD 308 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teladoc Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477449-26-000010), on February 25, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2614056348"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614056348\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614056348?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614056348","market":"us","top_or_hot":-1,"title":"Teladoc posts FY 2025 net loss of USD 200.3 million, down 80%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teladoc posts FY 2025 net loss of USD 200.3 million, down 80%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Teladoc Health reported Q4 2025 revenue of USD 642.3 million (flat), with net loss of USD 25.1 million and adjusted EBITDA of USD 83.8 million (+12%). For FY 2025, revenue was USD 2.53 billion (-2%), net loss was USD 200.3 million, adjusted EBITDA was USD 281.1 million (-10%), operating cash flow was USD 294.4 million (flat) and free cash flow was USD 166.9 million (-2%); the company ended 2025 with USD 781.1 million in cash and cash equivalents. In Q4, Integrated Care revenue was USD 409.1 million (+5%) while BetterHelp revenue was USD 233.2 million (-7%); Integrated Care adjusted EBITDA was USD 65.3 million (+23%) and BetterHelp adjusted EBITDA was USD 18.5 million (-15%). Teladoc Health said it strengthened its product portfolio and advanced innovation across Integrated Care and BetterHelp, while maintaining a focus on disciplined execution and leveraging technology to meet evolving client and member needs. For FY 2026, Teladoc Health guided for revenue of USD 2.47 billion to USD 2.587 billion and adjusted EBITDA of USD 266 million to USD 308 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477449-26-000010), on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc posts FY 2025 net loss of USD 200.3 million, down 80%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc posts FY 2025 net loss of USD 200.3 million, down 80%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-26 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teladoc posts FY 2025 net loss of USD 200.3 million, down 80%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Teladoc Health reported Q4 2025 revenue of USD 642.3 million (flat), with net loss of USD 25.1 million and adjusted EBITDA of USD 83.8 million (+12%). For FY 2025, revenue was USD 2.53 billion (-2%), net loss was USD 200.3 million, adjusted EBITDA was USD 281.1 million (-10%), operating cash flow was USD 294.4 million (flat) and free cash flow was USD 166.9 million (-2%); the company ended 2025 with USD 781.1 million in cash and cash equivalents. In Q4, Integrated Care revenue was USD 409.1 million (+5%) while BetterHelp revenue was USD 233.2 million (-7%); Integrated Care adjusted EBITDA was USD 65.3 million (+23%) and BetterHelp adjusted EBITDA was USD 18.5 million (-15%). Teladoc Health said it strengthened its product portfolio and advanced innovation across Integrated Care and BetterHelp, while maintaining a focus on disciplined execution and leveraging technology to meet evolving client and member needs. For FY 2026, Teladoc Health guided for revenue of USD 2.47 billion to USD 2.587 billion and adjusted EBITDA of USD 266 million to USD 308 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477449-26-000010), on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL6fcfQY:1","article_id":"2614056348","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614056348","pubTimestamp":1772053639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Teladoc Health reported Q4 2025 revenue of USD 642.3 million , with net loss of USD 25.1 million and adjusted EBITDA of USD 83.8 million . For FY 2025, revenue was USD 2.53 billion (-2%), net loss was USD 200.3 million, adjusted EBITDA was USD 281.1 million , operating cash flow was USD 294.4 million  and free cash flow was USD 166.9 million (-2%); the company ended 2025 with USD 781.1 million in cash and cash equivalents. In Q4, Integrated Care revenue was USD 409.1 million (+5%) while BetterHelp revenue was USD 233.2 million (-7%); Integrated Care adjusted EBITDA was USD 65.3 million  and BetterHelp adjusted EBITDA was USD 18.5 million . Teladoc Health said it strengthened its product portfolio and advanced innovation across Integrated Care and BetterHelp, while maintaining a focus on disciplined execution and leveraging technology to meet evolving client and member needs. For FY 2026, Teladoc Health guided for revenue of USD 2.47 billion to USD 2.587 billion and adjusted EBITDA of U","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","TDOC":"Teladoc Health Inc.","BK4167":"医疗保健技术","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4504":"桥水持仓","BK4585":"ETF&股票定投概念","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4588":"碎股","BK4567":"ESG概念"},"translate_title":"Teladoc公布2025财年净亏损2.003亿美元，下降80%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TDOC":0.9},"content_text":"Teladoc posts FY 2025 net loss of USD 200.3 million, down 80%\n    \n\n        Teladoc Health reported Q4 2025 revenue of USD 642.3 million (flat), with net loss of USD 25.1 million and adjusted EBITDA of USD 83.8 million (+12%). For FY 2025, revenue was USD 2.53 billion (-2%), net loss was USD 200.3 million, adjusted EBITDA was USD 281.1 million (-10%), operating cash flow was USD 294.4 million (flat) and free cash flow was USD 166.9 million (-2%); the company ended 2025 with USD 781.1 million in cash and cash equivalents. In Q4, Integrated Care revenue was USD 409.1 million (+5%) while BetterHelp revenue was USD 233.2 million (-7%); Integrated Care adjusted EBITDA was USD 65.3 million (+23%) and BetterHelp adjusted EBITDA was USD 18.5 million (-15%). Teladoc Health said it strengthened its product portfolio and advanced innovation across Integrated Care and BetterHelp, while maintaining a focus on disciplined execution and leveraging technology to meet evolving client and member needs. For FY 2026, Teladoc Health guided for revenue of USD 2.47 billion to USD 2.587 billion and adjusted EBITDA of USD 266 million to USD 308 million.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teladoc Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477449-26-000010), on February 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}